ENDOTHELIAL DYSFUNCTION AS CORNERSTONE OF CARDIOVASCULAR EVENTS: MOLECULAR AND PHARMACEUTIC ASPECTS

Abstract

The review concerns on the data about ED in CVD pathogenesis as the leading cause of death. The morphofunctional characteristic of endothelium is discussed, its synthetic activity and regulators. Also the regulatory role of NO-synthase and its gene polymorphism, as their clinical significance as the ED development factors. Also the vasodilator and vasoconstrictor balancing mechanisms of ET, showing different functions. Polymorphism of genes influences ET-1 activity, that has significant value for RAAS regulation with ACE and the influence of rare polymorphisms in CHD risk, MI, diabetic nephropathy. Pathogenetic significance of ED in the conditions of oxidative stress defines clinicists attention onthis pathology, related to atherosclerosis, and molecular and genetic aspects of CHD formation do dictate inevitability of personalized medicine for prognosis and prevention, as pharmacogenomics – for endothelial pathology correction of cardiovascular system in general.

Keywords

• endothelial dysfunction
• cardiovascular morbidity
• nitric oxide
• nosynthase
• endothelin-1
• angiotensin-converting enzyme
• pharmacogenomics
• personalized medicine